New PET tracer aims to catch a dangerous transplant complication early

NCT ID NCT03367962

Completed Diagnosis Sponsor: CellSight Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small Phase 1 study tested whether a radioactive tracer called [18F]F-AraG can help detect graft-versus-host disease (GVHD) using PET scans. GVHD is a serious condition where donor immune cells attack the recipient's body after a stem cell transplant. The study involved 9 patients who were either suspected of having acute GVHD or at high risk for it. Researchers compared the PET scan images with biopsy results to see if the tracer could identify areas of T cell activity linked to the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]F-AraG (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a non-invasive way to detect graft-versus-host disease earlier and more accurately than current methods.
What could go wrong: This was a very small, early-phase study with only 9 participants, and it did not include healthy volunteers as planned. The results may not apply to all patients, and the tracer is not yet proven as a reliable diagnostic tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

Stanford Hospital

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.